Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CMOPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CMOPF and 80,000+ other tickers.
See exactly how CMOPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CMOPF and 80,000+ other tickers.
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers…
Cosmo N.V. (CMOPF) Q2 2026 Earnings Call Transcript
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
Cosmo Pharmaceuticals (OTC: CMOPF - Get Free Report)'s stock price was up 1.1% during trading on Friday. The stock traded as high as C$135.00 and last traded at C$135.00. Approximately 558 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 1,186 shares. The stock had previously closed at
Cosmo Pharmaceuticals (CMOPF) just delivered the kind of data that can shift an entire market narrative. After releasing late-stage results for its experimental